Solanezumab: Information on the Clinical Trial

Contributed by: Dennis Fortier, President, Medical Care Corporation

The phase III clinical trial (EXPEDITION2) for Solanezumab is now open and enrolling patients.

Participants must be over the age of 55, be diagnosed with mild to moderate AD, and have an MMSE score of 16 through 26 in addition to a few other criteria (here) related to other health conditions and medications.

This is the third of three interesting drugs in phase III right now (Dimebon and Bapineuzumab) that could take us much closer to effective treatment for Alzheimer's disease.

1 comment :

  1. I would like my brother to go on a clinical trial for Alzheimers. He has mild alzheimers, aged 77. Could you please give me any information on trials in UK, my email address is: Many thanks